Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting-Reference-Cited by-同舟云学术

Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting

Published:2017-10-04 Issue:56 Volume:8 Page:96048-96061
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Riedl Jakob Michael¹,Posch Florian¹,Moik Florian¹,Bezan Angelika¹,Szkandera Joanna¹,Smolle Maria Anna¹,Kasparek Anne-Katrin¹,Pichler Martin¹²,Stöger Herbert¹,Stotz Michael¹,Gerger Armin¹³

Affiliation:

1. Division of Clinical Oncology, Department of Medicine, Comprehensive Cancer Center Graz, Medical University of Graz, 8036 Graz, Austria

2. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA

3. Center for Biomarker Research in Medicine, 8010 Graz, Austria

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel;Scientific Reports;2024-07-23

2. The Predictive Value of Inflammatory Markers, Prealbumin, and Albumin in the Clinical Efficacy of PD-1 Therapy in Advanced Solid Tumor Patients;Advances in Clinical Medicine;2024

3. Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study;Journal for ImmunoTherapy of Cancer;2023-12

4. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel;2023-11-29

5. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel: a pooled analysis of two retrospective studies in Japan;2023-07-12